Synergy Pharmaceuticals to Present at Two Upcoming Investor Conferences NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that President and CEO Gary S. Jacob, Ph.D., will be presenting a corporate overview at two healthcare conferences at the Waldorf Astoria Hotel in New York this month. *15th Annual BIO CEO & Investor Conference, hosted by the Biotechnology Industry Organization (BIO), on Monday, February 11^th at 1:00 p.m. EST in the East Foyer *Leerink Swan Global Healthcare Conference on Wednesday, February 13^th at 9:00 a.m. EST in the Metropolitan Suite Live audio webcasts of both presentations will be available under the investor relations section of Synergy's website at www.synergypharma.com. Replays of the presentations will be available for 30 days afterward. About Synergy Pharmaceuticals, Inc. Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's lead proprietary drug candidate, plecanatide, is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a positive Phase I study of plecanatide in healthy volunteers, and positive Phase IIa and Phase IIb/III clinical trials in patients with chronic idiopathic constipation (CIC). Detailed positive findings from a recently completed 948 patient CIC clinical will be presented at a major scientific meeting this year. Synergy is also developing plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C), having initiated the first trial in IBS-C patients in late 2012. Synergy's second GC-C agonist, SP-333, is in clinical development to treat inflammatory bowel diseases, and has just completed its first Phase I trial in healthy volunteers. More information is available at http://www.synergypharma.com. CONTACT: Media Contact: Janet Skidmore Office: 215-658-4915 Mobile: 215-429-2917 email@example.com Investor Contact: Danielle Spangler The Trout Group firstname.lastname@example.org (646) 378-2924
U.S. Natural Gas Futures Drop Below $3 for First Time Since 2012
Synergy Pharmaceuticals to Present at Two Upcoming Investor Conferences
Press spacebar to pause and continue. Press esc to stop.